#116 Nature's Balance Sheet: How GSK Turned Water Risk Into Pharma's First Science-Based Target

We explore how GSK became the first pharma company with a validated nature target and what that means for the sector. The piece covers the company's water and carbon progress, its plan to cut Ventolin inhaler emissions by 92%, a new global standard for measuring drug footprints, and the challenges that still stand in the way.